Goldline Pharmaceutical Limited

BSE: 544759
Goldline Pharmaceutical Limited - pharma in Nagpur, Maharashtra, India. FY 2026 financials & compliance.
CIN U51397MH2004PLC147806 Incorporated 02 August 2004 ROC Mumbai HQ Nagpur, Maharashtra, India
Active Listed - BSE: 544759 Public Limited Company pharma MSME · Small
Data last updated
Market Cap
₹28.78 Cr
GLPL · BSE
Share Price
₹30.10
+0.40% today
Revenue
₹31.20 Cr
FY 2025-26 · +11.2% YoY
EBITDA
₹7.06 Cr
Margin 22.6%
Net Profit
₹4.10 Cr
FY 2025-26 · +40.4% YoY
ROE
39.3%
ROCE 29.3%
Debt / Equity
0.82
Interest cover 21.4x
Authorised capital
₹13.5 Cr
Registered with MCA

About Goldline Pharmaceutical Limited

Data last updated:

Goldline Pharmaceutical Limited is a public limited company based in Nagpur, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 02 August 2004 and has been in existence for over 22 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51397MH2004PLC147806. Its GSTIN is 27AACCG2989F1ZE (Maharashtra). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 544759.

The company has an authorised share capital of ₹13.5 Cr and a paid-up capital of ₹8.71 Cr. It was formerly known as Goldline Pharmaceutical Private Limited. It is led by directors including Amol Laxmikant Mujumdar (Managing Director) and Swapan Khandelwal (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Nagpur, Maharashtra.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹31.2 Cr, a growth of 11.2% compared to the previous year. For the same year it recorded a net profit of ₹4.1 Cr (net margin 13.1%) and EBITDA of ₹7.06 Cr (EBITDA margin 22.6%). The net worth stands at ₹14.25 Cr (up 38.9% YoY). Total assets are valued at ₹24.46 Cr (up 10.3% YoY).

The company has about 85 employees on its provident fund (EPFO) records.

As per MCA filings, the company has open charges of ₹8.54 Cr and satisfied charges of ₹3.53 Cr on record. Court records list 3 cases involving the company, including 3 filed against it; 1 case is pending. The company has 24 deals on record (23 market trades, 1 ipo); the latest was in September 2026.

Goldline Pharmaceutical Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-20-0029654). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website goldlinepharma.in.

Company details

CIN U51397MH2004PLC147806
Registration Number 147806
Incorporation Date 02 August 2004
ROC Mumbai
Listing Status Listed - Listed on BSE (544759)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-20-0029654

CIN history

Goldline Pharmaceutical has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U51397MH2004PLC147806, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U51397MH2004PLC147806Current
U51397MH2004PTC147806Previous
L51397MH2004PLC147806Previous
Key People
Amol Laxmikant Mujumdar Managing Director Swapan Khandelwal Whole-Time Director Mehul Hari Ranade Director

Recognitions & Rankings of Goldline Pharmaceutical

MSME (Udyam registered) Ministry of MSME
Category
Small (2024-25)
Udyam number
UDYAM-MH-20-0029654

Contact details

Goldline Pharmaceutical Limited's registered office is in Nagpur, Maharashtra. Its website is goldlinepharma.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    goldlinepharma.in
  • Registered Address
    103 F – 1 Leelaapartmentshilpahsgsociety Nearsaptagirinagar Shanidham Narend, Ra Nagar, Nagpur, Maharashtra, India – 440015
  • Industry
    Pharma, Pharmaceutical Retailers & Distributors

To see the full contact details of Goldline Pharmaceutical Limited, buy the company report.

Comprehensive company report
Goldline Pharmaceutical Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Goldline Pharmaceutical is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Goldline Pharmaceutical Limited, buy the company report.

Financials of Goldline Pharmaceutical Limited

FY 2025-26 filings available

Goldline Pharmaceutical Limited reported revenue of ₹31.2 Cr (up 11.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹31.20 Cr
+11.2% YoY
EBITDA
₹7.06 Cr
+16.3% YoY
Profit After Tax
₹4.10 Cr
+40.4% YoY
Net Worth
₹14.25 Cr
+38.9% YoY
Total Assets
₹24.46 Cr
+10.3% YoY
Total Debt
₹9.16 Cr
-17.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue31.2028.0623.5719.85
Revenue growth+11.2%+19.1%+18.7%-
EBITDA7.066.074.322.22
EBITDA margin+22.6%+21.6%+18.3%+11.2%
Profit before tax5.363.872.550.41
Net profit4.102.921.860.39
Net profit margin+13.1%+10.4%+7.9%+2.0%
EPS (₹)5.974.117.851.28
Balance sheet
Total assets24.4622.1719.7917.40
Net worth14.2510.267.875.89
Total debt9.1611.0411.1310.83
Cash & bank0.591.240.790.05
Net working capital21.6319.3416.4214.84
Cash flow
Cash from operations2.813.182.922.39
Cash from investing(0.06)0.16(1.11)(1.04)
Cash from financing(3.40)(2.89)(1.08)(1.44)
ParticularsMar 2026Dec 2025
Revenue9.797.51
Other income0.000.00
Total expenses7.015.99
EBITDA2.781.52
EBITDA margin+28.4%+20.2%
Depreciation0.060.06
Interest0.350.30
Profit before tax2.371.16
Tax0.480.29

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsMar 2026Dec 2025
Revenue9.797.51
Other income0.000.00
Total expenses7.015.99
EBITDA2.781.52
EBITDA margin+28.4%+20.2%
Depreciation0.060.06
Interest0.350.30
Profit before tax2.371.16
Tax0.480.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue31.2028.0623.5719.85
Revenue growth+11.2%+19.1%+18.7%-
Other income0.000.000.000.00
Total expenses24.1421.9919.2517.63
Employee cost5.714.714.694.63
EBITDA7.066.074.322.22
EBITDA margin+22.6%+21.6%+18.3%+11.2%
Depreciation0.240.250.160.18
Interest1.461.951.611.63
Profit before tax5.363.872.550.41
Tax1.261.020.720.15
Net profit4.102.921.860.39
Net profit margin+13.1%+10.4%+7.9%+2.0%
EPS (₹)5.974.117.851.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital8.718.714.113.81
Reserves & surplus5.541.553.762.08
Shareholders' funds (net worth)14.2510.267.875.89
Secured loans6.616.677.156.90
Unsecured loans2.554.373.983.93
Total debt9.1611.0411.1310.83
Total liabilities24.4622.1719.7917.40
Assets
Gross block3.763.713.522.92
Net block2.702.892.952.50
Capital work in progress0.000.000.450.00
Investments0.030.030.030.07
Inventories6.216.787.495.37
Sundry debtors16.1310.699.628.63
Cash & bank balances0.591.240.790.05
Loans & advances3.114.551.602.77
Total current assets26.0423.2619.5016.82
Total current liabilities4.413.923.081.98
Net working capital21.6319.3416.4214.84
Total assets24.4622.1719.7917.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1.240.790.050.14
Net cash from operating activities2.813.182.922.39
Net cash from investing activities(0.06)0.16(1.11)(1.04)
Net cash from financing activities(3.40)(2.89)(1.08)(1.44)
Net change in cash(0.65)0.450.74(0.09)
Closing cash0.591.240.790.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+11.2%+19.1%+18.7%-
EBITDA growth+16.3%+40.5%+94.6%-
PBT growth+38.5%+51.8%+522.0%+9997.0%
Net income growth+40.4%+57.0%+376.9%-
Revenue CAGR (3Y)+16.3%---
EBITDA CAGR (3Y)+47.1%---
Profitability & leverage
Net income margin+13.1%+10.2%+7.8%+1.3%
Return on capital employed+29.3%+27.6%+22.3%+12.8%
Return on net worth+39.3%+38.7%+35.7%+9.6%
Debt / equity0.821.221.601.84
Long-term debt / equity0.190.400.570.65
Interest cover21.4133.5138.7079.90
Efficiency & per share
Fixed asset turnover8.357.767.326.80
Inventory turnover4.803.933.673.70
Debtors turnover2.332.762.582.30
EPS (₹)5.974.117.851.28
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)18.0312.2526.3420.42

To see the full year-wise statements and ratios of Goldline Pharmaceutical Limited, buy the company report.

Board of directors of Goldline Pharmaceutical Limited

Goldline Pharmaceutical has 8 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Swapan Khandelwal
Also directs: Cherry Voyaging Private Limited, Activista Healthcare Private Limited, Nucleage Lifesciences Private Limited and 4 more
Whole-Time Director11 Apr 201115 Years 6 MonthsCurrent
Amol Laxmikant Mujumdar
Also directs: Cherry Voyaging Private Limited
Managing Director02 Aug 200422 Years 2 MonthsCurrent
Mehul Hari Ranade
Also directs: Mumukshu Management Services LLP, Jiya Eco-Products Limited, Asud Renewables Private Limited and 1 more
Director30 Sep 20242 Years 0 MonthsCurrent
Prashant Shrikrishna KarkareDirector16 Jul 201313 Years 3 MonthsCurrent
Renuka Saurabh Borole
Also directs: Jiya Eco-Products Limited, Dra Consultants Limited
Director30 Sep 20242 Years 0 MonthsCurrent
Shraddha Kiran KulkarniDirector17 Oct 20242 Years 0 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Auditor

Goldline Pharmaceutical Limited is audited by SHAH & RAUT for the financial year 2023.

Auditor firmFinancial yearFirm registration number
SHAH & RAUTFY 2023121020W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 59.50%, foreign institutional investors hold 0.30%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 40.10%.

Promoters: 59.50%DII (Domestic Institutional): 0.10%FII (Foreign Institutional): 0.30%Retail & Others: 40.10%
Sep 2026
QUARTER
59.50% Promoters
0.10% DII (Domestic Institutional)
0.30% FII (Foreign Institutional)
40.10% Retail & Others
Shareholding trend - last 6 quarters
Sep 2026
Promoters59.50%
Public40.50%

Charges & borrowings

Open charges
₹8.54 Cr
Satisfied charges
₹3.53 Cr
Breakdown by lending institutions
Bank of India₹8.11 Cr
Others₹0.42 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
12 Dec 2024101015954Others₹42.1 LakhOpen
02 May 2022100575355Bank of India₹46 LakhOpen
16 Jan 201310410284Bank of India₹7.65 CrOpen
27 Dec 2013100814496Bank of India₹8 LakhSatisfied
17 Feb 201110273836State Bank of India₹3.45 CrSatisfied

To see the full charge records of Goldline Pharmaceutical Limited, buy the company report.

Total charge records: 5 View all charges

Deals & funding

Goldline Pharmaceutical Limited has 24 deals on record (23 market trades, 1 ipo); the latest was in September 2026.

Total deals
24
Market trades
23
IPO
1

Deals on record (5 of 24)

WhenDealAmountParties
Aug 2026Market trade₹83 LakhBuyer: 3 individuals
Seller: Cumulative Capital Private Limited , 2 individuals
Aug 2026Market trade₹19.8 LakhBuyer: Cumulative Capital Private Limited
Seller: Upsurge Opportunities Fund 1
Aug 2026Market trade₹71.3 LakhBuyer: Samurai Securities Private Limited , an individual
Seller: Upsurge Opportunities Fund 1, Samurai Securities Private Limited , an individual
Jul 2026Market trade₹98.4 LakhBuyer: 2 individuals
Seller: Amjay Impex Private Limited , 2 individuals
Jul 2026Market trade₹63.4 LakhBuyer: Amjay Impex Private Limited
Seller: an individual

To see the full deal history of Goldline Pharmaceutical Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Goldline Pharmaceutical Limited was last rated by Crisil on 19 Oct 2020.

Rating agencyRated onRating
Crisil19 Oct 2020

To see the full credit ratings and regulatory alerts of Goldline Pharmaceutical Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Goldline Pharmaceutical Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Goldline Pharmaceutical Limited has a workforce of 85 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.

Employee count
85
Active EPFO establishments
1
Employee growth
-19.81%

GST

Goldline Pharmaceutical has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AACCG2989F1ZEMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Goldline Pharmaceutical Limited, buy the company report.

Recent activity

Goldline Pharmaceutical Limited has 13 board changes on record since 2004: 8 appointments and 5 cessations. The latest: Shraddha Kiran Kulkarni ceased to be Additional Director on 29 Sep 2025.

Filing
Goldline Pharmaceutical Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai.
AGM
Goldline Pharmaceutical Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Shraddha Kiran Kulkarni ceased to be Additional Director.
Charges
A charge with Others amounted to Rs. 0.42 Cr with Charge ID 101015954 was registered on 12 Dec 2024.
Charges
A charge registered on 27 Dec 2013 via Charge ID 100814496 with Bank Of India was fully satisfied on 05 Dec 2024.
Appointed
Shraddha Kiran Kulkarni was appointed as Director.
Appointed
Mehul Hari Ranade was appointed as Director.
Appointed
Prashant Vithalrao Rahate was appointed as Director.
Appointed
Renuka Saurabh Borole was appointed as Director.
Ceased
Dhanraj Karbhari Chavan ceased to be Director.
Charges
A charge with Bank Of India amounted to Rs. 0.46 Cr with Charge ID 100575355 was registered on 02 May 2022.
Charges
A charge with Bank Of India of Rs. 7.65 Cr registered on 16 Jan 2013 with Charge ID 10410284 was modified on 15 Dec 2021.

12 earlier events are in the company report.

News

Frequently asked questions

Goldline Pharmaceutical is an active public limited company based in Nagpur, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 02 August 2004 (22+ years old) and is registered under CIN U51397MH2004PLC147806. Listed on BSE: 544759.

Goldline Pharmaceutical reported revenue of ₹31.2 Cr for FY 2025-26 (up 11.2% YoY) based on standalone financials.

Goldline Pharmaceutical has 8 current directors:

The latest financial statements of Goldline Pharmaceutical on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Goldline Pharmaceutical is 27AACCG2989F1ZE, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Goldline Pharmaceutical is U51397MH2004PLC147806. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Goldline Pharmaceutical is a listed company as per MCA records. Its shares are listed on BSE (code: 544759).

Goldline Pharmaceutical has 3 court cases on record: 3 filed against it. 1 is pending.

Goldline Pharmaceutical was incorporated on 02 August 2004, making it 22+ years old. It is registered with the Registrar of Companies, Mumbai.

Goldline Pharmaceutical has 24 deals on record (23 market trades, 1 ipo); the latest was in September 2026.